Newton Fund - DEVELOPMENT OF DIFFERENTIATED PRODUCT CONCEPTS FOR INSULIN GLARGINE

点击翻译按钮获取中文摘要

Availability of low cost insulin products, particularly products that can be distributed and used outside the coldchain is critical to developing an effective healthcare system that can deal with the rapidly increasing incidenceof diabetes. This project will combine the expertise and technologies of Arecor and Cadila Pharmaceuticals todevelop a innovative, low cost basal insulin product that can be distributed and used outside the cold chain. Inaddition validated technology will be employed to extend the duration of action of insulin glargine withbeneficial consequences to the control of hypoglycaemia. The scope of the project will allow formulationdevelopment and optimisation, stability testing and pre-clinical development. Following successful completionof the project, the project partners will progress the asset into clinical development and commercialisation. Thefinal product, which will draw on Arecor’s proprietary formulation technologies and Cadila’s excellent trackrecord in therapeutic development and commercialisation, will represent an attractive commercial opportunityas well as having a strong positive impact on the economic development and social welfare in India.